In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Local intratumoral treatment of glioblastoma with retrograde microdialysis of Cisplatin – pilot experiment

    Final Number:
    1172

    Authors:
    Pedram Tabatabaei Shafiei MD; Per Bergström MD, PhD; Mikael Johansson M.D, PhD; Thomas Asklund M.D, PhD; Tommy A. Bergenheim MD, PhD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2012 Annual Meeting

    Introduction: One factor limiting chemotherapy of brain tumours is the blood/brain barrier hampering drugs to enter the tumour/brain. Interstitial delivery of drugs may increase the therapeutic efficacy and reduce systemic side effects. In this study we have utilised the technique of microdialysis for delivering Cisplatin to glioblastoma tissue. We also intended to simultaneously monitor the metabolic effect induced by the treatment.

    Methods: In vitro Microdialysis catheters (100 kDa cutof) were applied within a buffer solution resembling the extra cellular fluid in the brain. The system was thereafter run with a perfusate containing Cisplatin at different concentrations and with different flow-rates. The buffer solution was analysed to evaluate amount of Cisplatin entering it. The results were used for calculating the doses and flow-rates in the clinical situation. In vivo Three patients with recurrent gliobastoma not suitable for further conventional treatment participated in the study. Two to three microdialysis catheters were implanted to tumour tissue by stereotactic technique. Our aim was to administer a dose of 1 mg/day Cisplatin for a period of 12 days.

    Results: In vitro Cisplatin can be delivered through the catheters at doses of 0.03 – 3 mg/day. The administrated dose can be controlled using different Cisplatin concentrations and flow-rates. In vivo Toxicity in terms of edema was observed within 6–8 days of treatment due to mainly ultrafiltration. This effect was reversible. However, the planned treatment of 12 days could not be archived. No significant regression of tumour mass could be observed radiologically. The treatment did not influence the glucose matabolism, however, in all patients the treatment induced an elevation of glutamate indicating a cytotoxic reaction induced by the treatment.

    Conclusions: 1 mg/day of Cisplatin can be administered to glioblastoma tissue using retrograde microdialysis. The technique seems feasable and apart from the edema induced the patients tolerated the procedure well. The clinical effect of the treatment was difficult to evaluate due to toxicity and few patients. The study will continue using catheters with lower cutof.

    Patient Care: Despite significant efforts the prognosis of malignant gliomas is still poor. Retrograde microdialysis may be an effective method to deliver interstitial chemotherapy to brain tumors bypassing the blood/brain barrier and reduce systemic side-effects.

    Learning Objectives: By taking part of the study, the reader will learn about the technique of retrograde microdialysis and its use in a pilot study administrating cisplatin to glioblastoma tissue.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy